• Endovastec, MicroPort Scientific's 40.32%-owned subsidiary, posted unaudited nine-month shareholder net profit growth of 4.55% to RMB 448.57 million through September 30, 2026.
• Revenue rose 10.26% to RMB 1.12 billion.
• Pretax profit increased 3.96% to RMB 517.27 million.
• Total assets reached RMB 5.04 billion at September 30, up 8.53% from December 31, 2025.
• Equity attributable to Endovastec shareholders grew 3.55% to RMB 4.22 billion over the same period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12388535), on October 29, 2026, and is solely responsible for the information contained therein.